birb 796 has been researched along with s 8932 in 1 studies
| Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (s 8932) | Trials (s 8932) | Recent Studies (post-2010) (s 8932) |
|---|---|---|---|---|---|
| 137 | 5 | 80 | 1,246 | 52 | 1,207 |
| Protein | Taxonomy | birb 796 (IC50) | s 8932 (IC50) |
|---|---|---|---|
| NS5 | Zika virus | 1.36 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.525 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asantewaa, G; Ciesla, JH; Dewhurst, S; Harris, IS; Leach, J; Lutz, MM; Monaghan, M; Munger, J; Raymonda, MH; Schafer, XL; Smorodintsev-Schiller, LA; Takimoto, T | 1 |
1 other study(ies) available for birb 796 and s 8932
| Article | Year |
|---|---|
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Benzoquinones; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Synergism; High-Throughput Screening Assays; Humans; Lactams, Macrocyclic; Lapatinib; Naphthalenes; Phenylurea Compounds; Pyrazoles; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |